Gallipoli et al. showed that the JAK1/2 inhibitor ruxolitinib synergized with nilotinib in inhibiting the proliferation of CD34+ cells in patients with CML [164]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.